A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants

Inclusion Criteria: * Females must have a negative pregnancy test. * Have a Basal Metabolic index (BMI) between 19 and 30 kg/m2 inclusive and weigh at least 50 kg. Exclusion Criteria: * History of any clinically significant disease or disorder. * History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * History of additional risk factors for Torsade de Pointes. * History of neoplastic disease. * Family history of sudden cardiac death. * Any skin condition likely to interfere with ECG electrode placement or adhesion. * Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of drug. * Any clinically significant abnormalities at screening and first admission in rhythm, conduction, or morphology of the 12-lead resting ECG and any clinically important abnormalities in the 12-lead ECG as considered by the investigator. * Participant has clinical signs and symptoms consistent with COVID-19. * Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening. * Positive screen for drugs of abuse, alcohol or cotinine at screening or on each admission to the Clinical Unit. * Participants who have previously received Baxdrostat. * Participants with any special dietary restrictions such as participants who are lactose intolerant or are vegeta…